Epoch Investment Partners Inc. Has $120.99 Million Stake in CVS Health Corporation $CVS

Key Points

• Epoch Investment Partners Inc. increased its stake in CVS Health Corporation by 49.5% in the first quarter, now owning approximately $120.99 million worth of shares.
• CVS Health reported better-than-expected quarterly earnings with an EPS of $1.81, surpassing the consensus estimate by $0.35, and generated revenues of $98.92 billion for the quarter.
• The company has announced a quarterly dividend of $0.665 per share, resulting in an annualized dividend yield of 3.7%.

Epoch Investment Partners Inc. boosted its stake in CVS Health Corporation (NYSE:CVS - Free Report) by 49.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,785,786 shares of the pharmacy operator's stock after purchasing an additional 591,209 shares during the period. Epoch Investment Partners Inc. owned about 0.14% of CVS Health worth $120,987,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of CVS. Goldman Sachs Group Inc. increased its holdings in CVS Health by 87.5% in the first quarter. Goldman Sachs Group Inc. now owns 9,927,650 shares of the pharmacy operator's stock valued at $672,598,000 after purchasing an additional 4,632,530 shares during the period. Dodge & Cox increased its holdings in CVS Health by 4.8% in the first quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator's stock valued at $4,976,856,000 after purchasing an additional 3,353,223 shares during the period. Nuveen LLC acquired a new stake in CVS Health in the first quarter valued at $204,421,000. Fairfax Financial Holdings Ltd. Can acquired a new stake in CVS Health in the fourth quarter valued at $121,742,000. Finally, Assenagon Asset Management S.A. increased its holdings in CVS Health by 310.8% in the first quarter. Assenagon Asset Management S.A. now owns 3,523,824 shares of the pharmacy operator's stock valued at $238,739,000 after purchasing an additional 2,666,029 shares during the period. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Stock Performance

Shares of CVS opened at $71.22 on Tuesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.80 and a quick ratio of 0.62. The stock has a 50-day moving average of $65.57 and a 200-day moving average of $65.37. The company has a market cap of $90.33 billion, a PE ratio of 19.89, a P/E/G ratio of 0.79 and a beta of 0.58. CVS Health Corporation has a one year low of $43.56 and a one year high of $72.51.

CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, beating the consensus estimate of $1.46 by $0.35. The company had revenue of $98.92 billion during the quarter, compared to the consensus estimate of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The firm's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period last year, the business posted $1.83 EPS. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts predict that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Tuesday, July 22nd were paid a $0.665 dividend. The ex-dividend date was Tuesday, July 22nd. This represents a $2.66 annualized dividend and a dividend yield of 3.7%. CVS Health's dividend payout ratio (DPR) is currently 74.30%.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Wells Fargo & Company restated an "overweight" rating and issued a $84.00 price objective (up from $76.00) on shares of CVS Health in a report on Tuesday, May 6th. Wall Street Zen upgraded CVS Health from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Bernstein Bank decreased their price target on CVS Health from $78.00 to $72.00 and set a "market perform" rating for the company in a report on Wednesday, July 16th. Cowen reiterated a "buy" rating on shares of CVS Health in a report on Monday, August 4th. Finally, Jefferies Financial Group increased their price target on CVS Health from $74.00 to $80.00 and gave the stock a "buy" rating in a report on Monday, June 30th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, CVS Health currently has a consensus rating of "Buy" and a consensus target price of $76.67.

Insider Activity at CVS Health

In other news, Director Guy P. Sansone bought 1,570 shares of CVS Health stock in a transaction dated Thursday, June 5th. The stock was bought at an average cost of $63.70 per share, for a total transaction of $100,009.00. Following the purchase, the director directly owned 12,007 shares in the company, valued at approximately $764,845.90. This represents a 15.04% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.22% of the stock is currently owned by corporate insiders.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.